Does anybody have ok communications with CANF IR, ask them how things are going with the Piclidenoson recruitment? I believe Topline data was slated for end of year 2021. They mentioned spending considerable funds on "accelerating rate of absorption of patients for the Phase III clinical trial of Piclidenoson".
I did send a query to IR, herewith the reply:
Thanks for your mail.
At this point, this is an internal information
which we will share with the public in due time.
Thanks for your interest,
Motti
Motti Farbstein
CFO